Literature DB >> 10980904

Platelet activation in acute myocardial infarction and the rationale for combination therapy.

I Conde-Pozzi1, N Kleiman.   

Abstract

Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.

Entities:  

Mesh：

Year:  2000        PMID： 10980904     DOI： 10.1007/s11886-000-0050-1

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  64 in total

1.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1988-12       Impact factor: 24.094

2.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.

Authors:  J A de Lemos; E M Antman; C M Gibson; C H McCabe; R P Giugliano; S A Murphy; S A Coulter; K Anderson; J Scherer; M J Frey; R Van Der Wieken; F Van De Werf; E Braunwald
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

3.  Differential effect of platelets on plasminogen activation by tissue plasminogen activator, urokinase, and streptokinase.

Authors:  S W Gao; J Morser; K McLean; M A Shuman
Journal:  Thromb Res       Date:  1990-05-15       Impact factor: 3.944

4.  Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.

Authors:  D J Fitzgerald; F Wright; G A FitzGerald
Journal:  Circ Res       Date:  1989-07       Impact factor: 17.367

5.  High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.

Authors:  S A Coulter; C P Cannon; K A Ault; E M Antman; F Van de Werf; A A Adgey; C M Gibson; R P Giugliano; M A Mascelli; J Scherer; E S Barnathan; E Braunwald; N S Kleiman
Journal:  Circulation       Date:  2000-06-13       Impact factor: 29.690

6.  Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators.

Authors:  S D Gertz; A H Kragel; J M Kalan; E Braunwald; W C Roberts
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

7.  Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

Authors:  N S Kleiman; A E Raizner; R Jordan; A L Wang; D Norton; K F Mace; A Joshi; B S Coller; H F Weisman
Journal:  J Am Coll Cardiol       Date:  1995-12       Impact factor: 24.094

8.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

9.  Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

10.  Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.

Authors:  J H Gurwitz; J M Gore; R J Goldberg; H V Barron; T Breen; A C Rundle; M A Sloan; W French; W J Rogers
Journal:  Ann Intern Med       Date:  1998-10-15       Impact factor: 25.391
View more
  1 in total

Review 1.  Nitric oxide, platelet function, myocardial infarction and reperfusion therapies.

Authors:  David Alonso; Marek W Radomski
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.